EMPRISE EMPAGLIFLOZIN REAL-WORLD EFFECTIVENESS
Live / Registered — Registered — Section 71 accepted (as of 09 Aug 2025)
What this means for you
Registered since 02 Jul 2019. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79249526
- Registration number
- 5791084
- Mark type
- Design + words
- Filed
- 28 Sept 2018
- Published for opposition
- 16 Apr 2019
- Registered
- 02 Jul 2019
- Attorney of record
- Max Moskowitz
Goods and services
- Class 042 — Scientific and technological services: Medical and scientific research in the field of diabetes, cardiovascular diseases and chronic kidney disease; Providing medical and scientific research information in the field of diabetes, cardiovascular diseases and chronic kidney disease
Owner
Prosecution history
- 09 Aug 2025 — NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
- 09 Aug 2025 — REGISTERED-SEC.71 ACCEPTED
- 28 Jul 2025 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 22 Apr 2025 — TEAS SECTION 71 RECEIVED
- 02 Jul 2024 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 01 Dec 2019 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 23 Oct 2019 — GENERIC MADRID TRANSACTION SENT TO IB
- 23 Oct 2019 — GENERIC MADRID TRANSACTION CREATED
- 02 Oct 2019 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 02 Jul 2019 — REGISTERED-PRINCIPAL REGISTER
- 06 May 2019 — CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
- 19 Apr 2019 — CORRECTION TRANSACTION RECEIVED FROM IB
- 16 Apr 2019 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 16 Apr 2019 — PUBLISHED FOR OPPOSITION
- 27 Mar 2019 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED